Ketalar (Ketamine)

Ketamine blocks the NMDA receptor by binding to its phencyclidine site, acting as a non‑competitive antagonist. This inhibition reduces excitatory glutamate signaling, leading to dissociative anesthesia, profound analgesia, and alterations in perception. The same mechanism also influences mood pathways, which underlies its investigational use in depression.

The dose of Ketalar is individualized and must be determined by a qualified prescriber based on the patient’s age, weight, clinical condition, and route of administration. Standard dosing regimens are outlined in professional guidelines, but exact amounts should always be set by the treating physician.

Safety data for ketamine during pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainty with patients and consider alternative agents when possible.

To order Ketalar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Ketalar (ketamine) differs from agents such as propofol or barbiturates by producing dissociative anesthesia rather than a classic hypnotic state. It maintains airway reflexes and cardiovascular stability better than many alternatives, but it carries a higher risk of psychotomimetic effects. Choice of agent depends on the clinical scenario, patient comorbidities and provider experience.

Ketalar should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Ketalar is supplied as an injectable solution for intramuscular or intravenous administration. The route, rate of injection and total dose are determined by the prescriber, often using a slow IV push for induction or a controlled infusion for maintenance of anesthesia or sedation.

The most critical risks include severe respiratory depression, airway obstruction, and emergence delirium or psychotomimetic reactions that may require intensive monitoring and supportive care. Cardiovascular spikes such as hypertension and tachycardia can also occur, especially in patients with pre‑existing heart disease.

Ketalar is contraindicated in patients with known hypersensitivity to ketamine or its excipients. Caution is advised for individuals with uncontrolled hypertension, severe coronary artery disease, elevated intracranial pressure, or a history of psychosis, as the drug may exacerbate these conditions.